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  Introduction 
According to the American Heart Association (AHA), ideal cardiovascular health is defined 
by the absence of any clinical manifestations of cardiovascular disease (CVD) and the presence of 
seven metrics, including not smoking, sufficient physical activity, a healthy diet, a normal body 
weight, an optimal total cholesterol level, an optimal blood pressure, and an optimal fasting glucose 
in the absence of any drug treatment (Mozaffarian et al., 2015). Clinical manifestations of CVD 
include heart failure (HF), heart attack, angina, hemorrhagic or ischemic stroke, and peripheral 
vascular disease. It is important to prevent CVD, because in 2011 the total direct and indirect cost 
of CVD in the U.S. was approximately $320 billion, which amounted to 15% of the total national 
health care expenditures (Mozaffarian et al., 2015). In addition, the AHA predicted that in the year 
2030, 43.9% of the U.S. population will have some form of CVD, and that the total direct medical 
costs of CVD will increase to $918 billion (Mozaffarian et al., 2015). Furthermore, the number one 
cause of death in the U.S. in 2009 was heart disease, with a total of 599, 413 deaths (Center for 
Disease Control and Prevention, 2012). Thus, it is important to prevent CVD to prevent unnecessary 
medical cost and to decrease morbidity.  
 HF, one of the clinical manifestations of CVD, is one of the most frequent causes of re-
hospitalization in the U.S., and it is associated with high rates of morbidity, mortality and cost 
(Center for Disease Control and Prevention, 2012). In 2012, an estimated 5.7 million Americans 
greater than 20 years old had HF, and by the year 2030, the prevalence of HF will increase by 46%, 
where greater than 8 million people over 18 years old will have HF (Mozaffarian et al., 2015). 
According to the 2015 AHA statistical update, in 2011 one in nine deaths was caused by HF 
(Mozaffarian et al., 2015). The prevalence of HF also increases with age, whereas the lifetime risk 
of developing HF for adults 40 years old and greater is one in five. Furthermore, in 2012, the total 
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cost of HF was approximately $30.7 billion, with a projected cost increase of 127% to $69.7 billion 
by the year 2030 (Mozaffarian et al., 2015). This means that the cost of HF in the U.S. will increase 
by $244 per every adult. Due to the high rates of prevalence, mortality and cost, it is important to 
prevent HF, and to treat HF according to current evidence-based therapy.  
 According to the American College of Cardiology Foundation/American Heart Association 
(ACCF/AHA) practice guidelines on the evaluation and management of HF, the standard therapy 
in all patients who had a recent or previous history of heart attack or acute coronary syndrome, 
regardless of the presence of HF, should be the prescription of angiotensin-converting enzyme 
inhibitors (ACEIs) and beta blockers (Yancy et al., 2013). In a comparative effectiveness review 
prepared by the Agency for Healthcare Research and Quality (AHRQ), adding ACEIs to the 
standard treatment of using beta-blockers can reduce total mortality and hospitalization related to 
HF (2010). Though ACEIs clearly benefit patients with HF, the rate of ACEI use is still relatively 
low due to its side effects of hypotension, hyperkalemia and cough (Gotsman, Rubovinich, & Azaz-
Livshits, 2008). 
 Though research showed that ACEIs helped in treating HF, literature showed that in the 
outpatient setting, there exist decreased rates of ACEIs prescriptions to HF patients which could be 
due to providers’ lack of HF guideline knowledge (Shafazand, Yang, Amore and O’Neal, 2010; 
Yancy et al., 2008), uncertainty about risk versus benefits in treating elderly patients since they are 
usually underrepresented in randomized controlled trials (Fuat, Hungin and Murphy, 2003; Yancy 
et al., 2008), and patient misperceptions to ACEI use (Yancy et al., 2008). Lee et al. (2005) also 
found that in HF patients with low-, average-, and high-risk group, ACEIs were prescribed at a rate 
of 81%, 73%, and 60% respectively. Furthermore, decreased adherence to guideline recommended 
treatment for HF could also be due to improper charting or the failure to account for 
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contraindications. Steinman et al. (2011) found that 87% of veterans received ACEIs, but when 
chart-documented reasons to not receive ACEIs were excluded, the rates increased to 95%. It is 
important to find out the reasons why there exist decreased rates of ACEI use by HF patients 
because it could represent missed opportunities for treatment by providers.  
 This Doctorate of Nursing Practice (DNP) practice inquiry project is made up of three 
manuscripts that explore the use of ACEI in the HF population. The first manuscript is a review of 
the 2013 HF guideline written by the ACCF/AHA Task Force. This manuscript explored the 
guideline in detail and compared it to another HF guideline for ease of applicability. The second 
manuscript explored the cost-benefit analysis of using coordinated healthcare delivery systems such 
as a patient centered medical home to reduce 30-day hospital readmission for HF exacerbation. The 
third manuscript describes a quality improvement project that focused on evaluating the use of 
ACEI in a primary care clinic for HF patients. A retrospective chart review with four objectives 
was performed in order to: 1) assess for frequency of documentation of an ACEI in current and 
active medication lists of patients with HF, 2) assess for documentation of ACEI type, dosages and 
dosing frequency in the EMR, 3) assess if an ACEI has been an active medication within a year 
prior to the patient encounter, and 4) assess for common documented reasons that HF patients are 
not on an ACEI. A focus group was held to discuss: 1) the barriers and facilitators to implementing 
ACEI therapy in HF patients in this clinic, 2) the barriers and facilitators to proper documentation 
of ACEI use in the clinic, and 3) what can be implemented to facilitate providers’ use of ACEI 
therapy in HF patients. Information from the three manuscripts will be used to educate providers 
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Analysis of Clinical Practice Guideline Paper on Heart Failure 
Heart failure, a manifestation of heart disease, is a chronic condition that causes 
progressive and debilitating damage to the body. This disease is one of the most frequent causes 
of re-hospitalization in the United States (U.S.), and it is associated with high rates of morbidity, 
mortality and cost (Centers for Disease Control and Prevention, 2012). According to the 
American Heart Association (2014), in 2010, one out of every three deaths is caused by 
cardiovascular disease, with a total mortality of approximately 2.5 million annually in the U.S. 
(Go et al., 2014). In 2009, the number one cause of death in the United States was heart disease, 
with a total of 599, 413 deaths (Centers for Disease Control and Prevention, 2012). In addition, 
in 2010, the estimated direct and indirect medical care cost related to cardiovascular disease was 
$315 billion (Go et al., 2014). 
Scope and Purpose 
Implemented as part of the Patient Protection and Affordable Care Act, starting in the fall 
of 2013, hospitals that have patients readmitted within 30 days of discharge due to heart failure 
will have reduced Medicare reimbursement, and in 2014, hospitals with high readmission rates 
might lose up to 3 percent of their regular Medicare reimbursement (Kaiser Health News, 2013). 
With these new rules, it is important for healthcare practitioners to prevent hospital readmission 
due to congestive heart failure (CHF). Many forms of treatment for heart failure have been 
devised, but these treatments need to be individualized to each patient in accordance with current 
guidelines. The three major patient outcomes from the treatment should include relief of 
symptoms and improved quality of life, slowing down of cardiac structure abnormalities and 
reduced mortality (Velez, Westerfeldt, & Rahko, 2008). 
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Since heart failure is a prevalent disease, it is important to treat it appropriately. The 
overall objective of the practice guideline written by the American College of Cardiology 
Foundation/American Heart Association (ACCF/AHA) Task Force is the improvement of the 
quality of care, optimization of patient outcomes, and reducing medical cost for HF patients 
(Yancy et al., 2013). In addition, the guideline is created to diagnose and manage the treatment 
of most HF patients. However, some patients’ treatment may deviate from the guideline because 
that is what is appropriate for the patient’s individual treatment. Thus, the use of this guideline 
will depend on the clinician’s judgment and the patient’s current condition. The guideline also 
recommends that clinicians should engage patients’ active participation in their medical 
treatment through shared decision making. This will help to ensure treatment is tailored to 
individual patient’s condition and preference. The purpose of this paper is to analyze the current 
HF guideline written by the ACCF/AHA Task Force and discuss how it was developed, when it 
should be used and how it compares to another HF guideline in terms of practicality and use.  
Stakeholder Involvement 
 This comprehensive heart failure (HF) guideline is developed in a joint effort by the 
ACCF and AHA. The writing committees were made up of experts in the evaluation and care 
management of heart failure patients, including physicians and a nurse (Yancy et al., 2013). The 
writing committee included general cardiologists, HF and transplant specialists, 
electrophysiologists, general internists, physicians with methodological expertise, and members 
from ACCF, AHA, the American Academy of Family Physicians, American College of Chest 
Physicians, the American College of Physicians, the Heart Rhythm Society, and the International 
Society for Heart and Lung Transplantation (Yancy et al., 2013).   
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 Only one nurse was included in the development of this guideline. The guideline 
committee should have included family and adult nurse practitioners. Nurse practitioners take 
care of HF patients in their daily practice, and as a result of their clinical experience with these 
patients, nurse practitioners could have provided valuable input to the development of the HF 
guideline. The writing committee members were diverse enough and included the necessary 
groups related to the topic of HF.  
Rigor of Development 
 The authors of the ACCF/AHA Task Force performed an extensive evidence review for 
literatures that included studies and reviews up to October of 2011, and some other literature 
references through April 2013. The search included publications in English from PubMed, 
EMBASE, Cochrane, Agency for Healthcare Research and Quality Reports and other databases 
related to HF but not named in the guideline. Some key words used for the searches included: 
heart failure, cardiomyopathy, hypertension, dyslipidemia, cardiac catheterization, angiotensin-
converting enzyme inhibitors, beta blockers, and cardiac resynchronization therapy (Yancy et al., 
2013). The authors performed a literature review of topics related to the guideline such as 
evidence for or against some tests, treatments or procedures for HF, estimates of expected 
outcomes, issues of patient preference that may influence treatment choice, and weighted the 
strength of evidence for or against a particular test or treatment for HF. However, the guideline 
authors did not specify the specific criteria used to select the evidence for the guideline.  
For the recommendation formulation, the authors used evidence-based methodologies 
developed by the task force, which included the Class of Recommendation and the Level of 
Evidence (Yancy et al., 2013). The Class of Recommendation (COR) estimated the size of 
treatment effect by considering the risk versus benefits of a treatment or procedure (Yancy et al., 
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2013). The COR used current evidence to determine whether a treatment or procedure would be 
useful or effective and whether it had the potential to cause harm (See Table 1). The Level of 
Evidence (LOE) gave an estimate of the level of certainty or precision of the effect of a treatment 
(Yancy et al., 2013). The authors reviewed the evidence and ranked it as LOE A, B, or C in order 
to support each recommendation in the guideline (See Table 1). For certain evidence where 
adequate data could not be obtained, recommendations were made based on expert consensus 
and clinical experience, and ranked as LOE C. If possible, any recommendations with LOE C 
were supported with historical clinical data and given appropriate references. In addition, if a 
recommendation with LOE C only had sparse supporting evidence, a survey of current practice 
among clinicians in the writing committee was used as the basis for LOE C with no reference 
cited. A summary table for COR and LOE was included in the guideline (See Table 1). 
Furthermore, this guideline separated the Class III recommendation to differentiate between 
recommendations that had “no benefit” or were associated with “harm” to the patient (Yancy et 
al., 2013).  
Since this HF guideline addressed patient populations and clinicians in North America, 
drugs not available in North America were discussed but not given a COR (Yancy et al., 2013). 
Also, studies not performed in North America were reviewed for potential influence on practice 
patterns and for any treatment effect and relevance on ACCF/AHA patient population. If the 
findings suggested a specific recommendation, it would be included in the guideline with 
relevant reference information (Yancy et al., 2013).  
 The ACCF/AHA guideline for the management of HF gave a clear description of the 
relationship between recommendations and the supporting evidence, which can be followed 
easily by readers and applied in the clinical setting. The recommendations were separated into 
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four parts, each with its own supporting evidence (Yancy et al., 2013). Authors of the guideline 
deemed that recommendations with an A level of supporting evidence had results from 
randomized clinical trials or meta-analysis, those with a B level of evidence had limited results 
from a single randomized trial or nonrandomized studies, and those with a C level of evidence 
had results from a limited sample population using consensus of expert opinion, standard of care 
or case studies (Yancy et al., 2013). A class I recommendation with an A level of evidence 
would have the strongest support and should be applied in the clinical setting. A class IIb 
recommendation with a C level of evidence represents results from expert opinions, case studies 
or standard of care. This type of recommendation was not well supported with evidence, and was 
not encouraged to be used in the clinical setting if not needed. A class III recommendation with 
an A level of evidence demonstrated with more than adequate results that the treatment or 
procedure could cause harm or provided no benefit for the patient, and should not be performed. 
A class III recommendation with a C level of evidence had results from expert opinions, case 
studies or standard of care, and the recommendations might be harmful or may not benefit the 
patient if performed. The recommendations were appropriate and were placed into categories 
according to the correct level of evidence. An example of a Class I with A level of evidence in 
the treatment recommendation is that “in patients with a history of myocardial infarction and 
reduced ejection fraction (EF), angiotensin converting enzyme inhibitors (ACEIs) or angiotensin 
II receptor blockers (ARBs) should be used to prevent HF”; while a harmful class III with C 
level of evidence recommendation is that nondihydropyridine calcium channel blockers may be 
harmful in patients with low left ventricle EF (Yancy et al, 2013).  
 Though the recommendations and the supporting evidence were clearly illustrated, the 
authors did not show the appropriate steps on how to update the current guideline. The guideline 
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only stated that the “ACCF/AHA Task Force were charged with developing, updating and 
revisiting practice guidelines for cardiovascular diseases and procedures” (Yancy et al, 2013, pg. 
e242). Steps for guideline updates should have been disclosed so that readers could keep up with 
the most up-to-date guideline and apply the most appropriate evidence-based practice in the 
clinical setting.  
Clarity and Presentation 
 This guideline gives specific and unambiguous recommendations. For example, for the 
clinical evaluation of HF patients, a class I recommendation for history and physical examination 
would include checking volume status and vital signs at each patient encounter, including serial 
weight, estimation of the jugular venous pressure and a check for the presence of peripheral 
edema (Yancy et al., 2013). This recommendation had a B level of evidence, so according to the 
authors, this recommendation should be performed because patients would benefit from it. 
Another example would be for the ambulatory setting, if a patient presented with dyspnea, 
authors recommended checking for biomarkers including BNP or N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) to support clinical decision in regards to HF diagnosis, 
especially if there was uncertainty in the diagnosis. This recommendation had an A level of 
evidence, which according to the authors should be done because it would benefit the patient. 
This guideline showed specific and unambiguous recommendations, which makes it easy to 
adapt in the clinical setting.  
 This guideline also gives different options for management of HF. An example would be 
for stage B HF with reduced ejection fraction (EF), in a class I recommendation, patients with a 
recent or previous history of myocardial infarction (MI) should be prescribed angiotensin-
converting enzyme inhibitors (ACEI) or an angiotensin II receptor blocker (ARB) if unable to 
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tolerate ACEI, in order to prevent symptomatic HF and to reduce mortality (Yancy et al., 2013). 
This recommendation had an A level of evidence. In addition, the authors also recommended the 
use of beta blockers for stage B HF with reduced EF in patients with a recent or previous history 
of MI to help reduce mortality (Yancy et al., 2013). This recommendation had a B level of 
evidence. This guideline clearly stated that ACEI should be prescribed for stage B HF with 
reduced EF, but if patients could not tolerate ACEI, ARB could be used as a substitute for it. In 
addition, beta blockers could be used if ACEI or ARB could not be tolerated but with a lower 
supporting level of evidence. Thus, the guideline suggests different management options for 
stage B HF with reduced EF, and allows clinicians some degree of freedom for patient treatment.  
 Lastly, in this current guideline, the key recommendations were written in boldface, so 
readers can easily recognize them. The use of boldface separates out the key recommendations 
from other explanations, so readers can quickly and easily locate the recommendations for easy 
application to the clinical setting. Also, the authors created tables for a summary of key 
recommendations for HF treatment. The tables are easy to follow, with clear explanations which 
reiterate key recommendations to readers. The guideline is user friendly and can easily be 
followed from one recommendation to the next.  
Application 
 This current HF guideline is comprehensive in that it includes many different 
management options for HF and even quality improvement metrics for HF. However, some of 
the treatment options could not be applied easily by all clinicians due to treatment complexities 
and cost. An example could be the cardiac resynchronization therapy (CRT). CRT, also called 
biventricular pacing, is a specialized pacemaker therapy where it paces the heart through 
multiple sites (Yancy et al, 2013). CRT is more commonly used for left bundle branch block to 
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promote synchrony between the right and left ventricles, and thus, improving the pumping 
efficiency of the heart (Shea, & Sweeney, 2003). Though this treatment can be performed by 
most electro physiologists, it should only be performed by clinicians in centers with the expertise 
and tools for it for better patient outcome. Since this treatment may incur a high cost, which 
should be covered by insurance if meeting the guideline implementation criteria, only treatment 
facilities with adequate financial capabilities offer this treatment (Yancy et al., 2013). In 
addition, continuous patient follow-up with cardiologist is essential for successful treatment. If 
the patient is not consistent in going to follow-up visits, this non-adherence may reduce the 
potential positive effect of the CRT treatment. The high cost and complexities of this treatment 
may serve as a barrier to implementation of this treatment by many healthcare organizations. In 
addition, some of the other treatments such as inotropic support for inpatient hospitalization 
should only be performed by centers that have a specialized cardiac unit for maximum 
utilization. A facility needs to have adequate staffing and expertise to open a specialized cardiac 
unit. Training staff and hiring the necessary experts to run the facility would require a lot of 
capital. Thus, not all recommendations in the guideline could be applied by every clinician due 
to the cost and complexities of the treatments recommended.  
 This guideline does not address some of the organizational barriers in treatment 
application and treatment cost implications. The lack of discussion on cost and barrier 
implications may hinder treatment application by clinicians who had the ability to use these 
treatments. Thus, the ACCF/AHA Task Force would need to discuss organizational barriers and 
cost implications in future guideline updates in order to allow clinicians greater understanding of 
the different treatment complexities and costs. A guideline with a clear discussion of treatment 
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options, complexities, and cost could reduce uncertainty and allow for easy application by 
clinicians.  
Theoretical Framework 
 In order to guide the application of this guideline to practice, clinicians must be educated 
continuously about the guideline. The concept of learning through continuous education could be 
explained well by Albert Bandura’s social learning theory. Bandura (1971) proposed that direct 
reinforcement could not account for all learning types, and that people could also learn through 
observing others, known as observational learning.  
In addition, Bandura (1971) believed that observational learning is guided by four 
interrelated processes: attention, retention, reproduction and reinforcement or motivational. In 
order to learn a new behavior, a person needs to pay attention, observe the behavior, retain the 
newly learned behavior in the memory bank, and draw out the stored behavior in the future. 
After learning the new behavior, it is important to reproduce the behavior and practice it so as to 
improve the behavior. Lastly, positive reinforcement makes a person perform the new behavior 
while negative reinforcement decreases a person’s motivation to perform the newly learned 
behavior (Bandura, 1971).  
Clinicians could use this theory to guide application of the HF guideline. Those in charge 
would need to draw their colleagues’ attention to the problems related to HF. They would need 
to find out why clinicians are not using the HF guideline and educate them about its importance. 
Positive reinforcements such as better patient outcomes and increased patient satisfaction with 
receiving the appropriate treatment will encourage clinicians to use the guideline more often.  
Continuous education about guideline applications would be the easiest and best way to ensure 
that clinicians understood the importance of using evidence-based therapy in treating HF 
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patients. Reminders about using the guideline and evidence-based therapies could be placed in 
the electronic health records or pamphlets could be placed in the exam rooms. The continuous 
presence of reminders will increase clinicians’ awareness, and hopefully increase the chances of 
clinicians using the HF guideline to treat HF patients.   
Editorial Independence 
 The American College of Cardiology Foundation and the American Heart Association 
(ACCF/AHA) sponsored the development of the guideline. The ACCF/AHA selected the expert 
authors to be on the guideline committee in order to create the current HF guideline. The 
ACCF/AHA explicitly stated that they did not influence the guideline’s development, and the 
authors examined evidence, reviewed it, and updated the guideline independently.  
 In addition, the ACCF/AHA task force made sure that no conflict of interest could arise 
due to author’s relationship with the health-care industry. The ACCF/AHA Task Force made it a 
necessity for the authors to disclose any health care relationship, from current ones to 12 months 
before the writing of the guideline (Yancy et al., 2013). In addition, the task force created a new 
policy that stated that the committee chair and a minimum of 50% of the writing committee had 
to have no relevant relationship with the health care industry (Yancy et al., 2013). Lastly, the 
authors disclosed any relationship they had with any industry in appendices one and two.  
Recommendation 
 Another guideline for HF was developed by the Heart Failure Society of America 
(HFSA) in 2010. This treatment guideline used three grades, A, B, and C to assess the strength of 
evidence, similar to the ACCF/AHA HF treatment guideline. But for the strength of 
recommendation, the HFSA used “totality of evidence,” which categorized recommendations 
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into several categories using phrases. The first recommendation, “is recommended,” meant the 
recommendation should be part of routine care with minimal exceptions, “should be considered” 
meant the recommendation should be applied to the majority of patients with exceptions for 
some individuals, “may be considered” meant that the therapy should be given on an 
individualized basis, and lastly, “is not recommended” meant the therapy should not be used 
(Lindenfeld et al., 2010). The strength of recommendation for the HFSA guideline is not as 
comprehensive as the recommendations in the ACCF/AHA guideline. In addition, the 
ACCF/AHA simplified the level of evidence and strength of recommendation in a table, but this 
is not the case in the HFSA guideline. The lack of comprehensive recommendation and 
simplicity in the HFSA guideline reduced ease of application in the clinical setting.  
 In the treatment recommendations, the guideline developed by the ACCF/AHA clearly 
differentiated the treatment options in bold font for simplicity but the HFSA did not differentiate 
the treatment options. In the HFSA guideline, it is more difficult to differentiate the treatment 
options from the rest of the treatment explanations. However, the HFSA provided a summary 
table for medication treatment and dosages for HF patients with reduced EF. This allows 
clinicians to apply the treatment easily in the clinical setting. The ACCF/AHA guideline did not 
give dosages for medication treatment, perhaps assuming that clinicians would know what 
dosages to start patients on. This lack of guidance might make it difficult for newly graduated 
clinicians to understand how to apply the guideline in the busy clinical setting.  
 Lastly, the ACCF/AHA guideline is easier to understand since the guideline compared 
each treatment and showed evidence on which treatments should be applied and which should 
not. The HFSA guideline did not compare treatments but explained each treatment in detail. The 
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detailed explanations were useful, but comparison of treatments should be added to help 
clinicians to understand which treatment performed better and should be given to patients.  
 The ACCF/AHA guideline seems preferable because the guideline was created in a 
simplistic way, easy for readers to understand and apply in the clinical setting. The tables in the 
guideline were clear and provided further detail. The guideline was not so long that it made it 
difficult for readers to read and understand. The guideline was created with the right amount of 
information so clinicians could self-study it and apply it in their daily practice.  
 Lastly, this guideline is preferable because it was created for general use in HF treatment. 
Any family nurse practitioner could read the guideline and apply the information in their daily 
practice. However, some of the more specialized treatment recommendations such as the CRT 
therapy or the heart transplant could not be performed by the nurse practitioner. These 
specialized therapies were written for cardiologists working in the hospital setting. It is important 
to practice evidence-based therapy in all clinical settings, especially to treat HF patients, because 
the healthcare cost of letting this condition go untreated could be high. Good evidence-based 
treatment could decrease the cost burden for this disease and benefit many people. Any nurse 
practitioner should read and understand this guideline, and use it in their daily clinical practice to 







A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical 
questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there 
may be a very clear clinical consensus that a particular test or therapy is useful or effective. 
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of 
diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. 
†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of 
comparator verbs should involve direct comparisons of the treatments or strategies being evaluated. 
 
Table 1. Applying Classification of Recommendation and Level of Evidence (Yancy et al., 
2013).  
 
Reprinted with permission: Circulation. 2013; 128: e240-e327. 2012 American Heart 
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Cost-benefit Analysis of a Patient Centered Medical Home for Reducing  
30-day Hospital Readmission for Heart Failure Exacerbation 
Heart failure (HF) is one of the most frequent causes of re-hospitalization in the United 
States (U.S.), and it is associated with high cost and high rates of morbidity and mortality.  In 
2009, the total hospitalization costs for heart failure in persons aged 65 years or older was 
estimated at $20.1 billion, and the average hospitalization cost per patient increased from $7,000 
in 1990s to $18, 086 currently (Wang, Zhang, Ayala, Walla, & Fang, 2010). According to the 
American Heart Association (AHA) 2014 statistical update, in 2010, one out of every three 
deaths was caused by cardiovascular disease, with a total mortality of 2,468,435 (Go et al., 
2014). In 2013, the number one cause of death in the United States was heart disease, with a total 
of 611,105 deaths (Centers for Disease Control and Prevention, 2014). In addition, in 2010 the 
estimated direct and indirect medical care cost related to cardiovascular disease was $315 billion 
(Go et al., 2014). Implemented as part of the Affordable Care Act, starting in the fall of 2013, 
hospitals will have reduced Medicare reimbursement if patients are readmitted for the diagnosis 
of heart failure (HF) within 30 days of discharge. In 2014, hospitals with high HF readmission 
rates could lose up to 3 percent of their regular Medicare reimbursement (Medicare Payment 
Advisory Commission, MedPAC, 2013). It is essential to prevent hospital readmission due to HF 
so hospitals will not lose part of their reimbursement and to improve the quality of life for 
patients with this chronic disease. 
Background 
In the U.S., preventable hospital readmissions can be costly to patients, hospitals and 
insurance companies. Among the Medicare population, an average of 20% of the patients were 
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readmitted within 30 days, and these readmissions cost Medicare an estimated 12 billion dollars 
each year (Thorpe, & Cascio, 2011). Hospital readmissions could signify poor quality of care, as 
well as poor coordination of care between primary care providers and acute care providers. 
Following the enactment of the 2010 Affordable Care Act, the Center for Medicaid Services 
(CMS) implemented the hospital readmissions reduction program (HRRP) in October of 2012 
(MedPAC, 2013). HRRP worked by reducing payments to hospitals that had excess preventable 
readmissions during the previous three years. In fiscal year 2013, the penalty was capped at one 
percent of inpatient base operating payments. This cap increased to two percent in 2014 and to 
three percent in 2015. The penalty will stay at three percent after 2015 (MedPAC, 2013). With 
the implementation of the HRRP, the goal is that hospitals will reduce readmission rates by 
improving their quality of care, coordinating discharges with primary care providers, and 
involving multidisciplinary members in the patients’ care both before and after discharge by 
using the patient-centered medical home (PCMH) model. The PCMH model is a 
multidisciplinary care system that seeks to provide comprehensive healthcare to patients and to 
ensure that the patient and family members are involved as core members of the team (Agency 
for Healthcare Research and Quality (AHRQ), 2012). The purpose of this cost-benefit analysis is 
to reduce the 30-day hospital readmission rate due to HF by employing a patient centered 
medical home (PCMH) model.  
Benefits of the PCMH Model  
The PCMH model was a part of the 2010 Patient Protection and Affordable Care Act. 
PCMH was developed in an effort to reduce the rising cost of healthcare, increase patient 
involvement in their care, result in better coordination between acute care providers and primary 
care providers, and improve quality of care (Berryman, Palmer, Kohl, & Parham, 2013). The 
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PCMH can be used as an effective framework for tailoring interventions for HF patients by 
producing measurable improvements in outcomes, such as reducing the rate of avoidable 
readmissions (Somers, & Cunningham, 2011). 
The PCMH model is a coordinated care delivery system that provides comprehensive 
primary and acute care services such as administering health risk assessments, providing 
preventive care services, and chronic condition management. The PCMH uses a team of 
physician-led healthcare providers for care provision. The team includes nurse practitioners, 
physician assistants, registered nurses, pharmacists, nutritionists, therapists and social workers, 
with the patient at the center of the care (Christensen et al., 2013). With this care model, the 
primary care provider will coordinate all the healthcare services that a patient needs, such as 
primary care services, specialty care, hospital care, home healthcare, and other supports (Rich, 
Lipson, Libersky, & Parchman, 2012). For example, if the patient needs home healthcare 
services, the primary care provider will coordinate this; and, if the patient requires rehabilitation 
services after a hospital stay, the primary care provider will coordinate this, and ensure that the 
patient is followed in order to prevent unnecessary readmissions (Rich, Lipson, Libersky, & 
Parchman, 2012). This concept of PCMH enables continuity of care, which helps to develop 
better patient-provider relationships, thus improving patient outcomes and reducing healthcare 
costs.  
Christensen et al. (2013) found the use of the PCMH model reduced hospital medical 
care costs by 11% for patients with chronic conditions, as compared to seven percent lower for 
those without a chronic condition. This shows the use of PCMH in treating patients with chronic 
conditions such as HF can have significant benefits, especially in terms of reducing costs to the 
healthcare system. One study found that this type of system could save as much as $4,845 per 
28 
 
patient for the healthcare system after accounting for the cost of implementation (Osei-Anto, 
Audet, Berman, & Jencks, 2010).  This is significant considering a recent study estimated the 
mean inpatient cost for HF patients is $9,923 per patient, and the 30-day readmission rate for 
these HF patients is 22.9% (AHRQ, 2012).  Inpatient hospital costs attributed to such 
readmissions can be up to $2,084 per patient per day (Casteel, 2012).   
Reid et al. (2010) did a two-group, quasi-experimental before-and-after evaluation study 
over two years to gauge a prototype PCMH’s impact on cost, quality and experience at a clinic in 
Seattle, Washington. 6,187 adult patients were surveyed at baseline, and at 12 months and 24 
months post PCMH formation, measuring patient experiences in care coordination, care access, 
goal setting, quality of doctor-patient interactions, and patient involvement. The study found that 
the PCMH model helped to improve patients’ experience and quality of care, reduced provider 
burnout, reduced emergency visits by 29 percent and hospitalization by six percent, and provided 
an estimated healthcare savings of $10.30 per patient per month after 21 months of program use. 
However, the major limitation of this study is that it is based on the result of one clinic. In order 
for the result to be generalizable, future studies should include a number of other clinics and a 
diverse patient population. Though the study only used results from one clinic, this prototype 
clinic showed that the PCMH care model can substantially reduce healthcare costs by reducing 
the healthcare expenditures, improving primary care delivery, and improving patient outcomes.  
Therefore, the PCMH model can be used to coordinate all the care for HF patients with a goal of 
reducing hospital readmission rates, reducing medical care costs and helping to improve 









Figure 1. Benefit model of PCMH 








PCMH Design  
The purpose of this paper is to recommend a PCMH program design that can help to 
coordinate the care of HF patients after hospital discharge. According to Berryman, Palmer, Kohl 
and Parham (2013, p. 166), the basic idea for a PCMH should include the following:  
• Presence of a relationship between the patient and the medical provider, 
• Presence of a provider who will take charge of all the care of the patient including 
arrangements for specialty care, 
• Continuous care that is managed by the same provider to guarantee care 
coordination and collaboration, 
• Transparent and fair payments with quality and safety as the key aspect of the 
system. 
The PCMH program will employ a primary care provider who will coordinate the care post 
discharge from the hospital and acquire all the needed information from the acute care provider. 
The primary care provider will then coordinate the patient’s care with the other interdisciplinary 
team members. The patient and family members will be involved throughout the process. Other 
interdisciplinary team members will include the nurse practitioner, heart failure registered nurse, 
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pharmacist, dietician, and social worker. The nurse practitioners will help the primary care 
provider monitor the patient’s condition post hospital discharge, and help to reiterate heart failure 
teaching each time the patient is seen. A heart failure registered nurse will follow up with the 
patient by calling him/her at home to answer any questions the patient may have. The pharmacist 
will monitor the patient’s lab values and adjust heart failure medications as needed. The dietician 
will work closely with the patient to create a plan for healthy living such as eating healthfully 
and exercising. Lastly, the social worker will work with the patient to provide materials or 
equipment needed for the patient’s home care.  





















In order to implement a PCMH program to treat HF patients in an existing hospital-
owned clinic, stakeholders will need to be invited to participate in the program. Before creating a 
budget plan, it is important to make sure that there are enough providers to handle the PCMH 
patient load, if not, more providers will need to be hired.  The number of providers needed will 
depend on the number of patients seen. At the same time, staff such as heart failure registered 
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nurses, pharmacists, dieticians, and social workers will need to be hired if none were present in 
the existing clinic. The number of staff will also depend on the patient load.  Clinic policies and 
standard operating procedures such as clinical practices, clinical documentation, client privacy 
rights and responsibilities, staff job descriptions, risk management, and admitting, discharging 
and referral procedures will need to be developed before the PCMH can be started. Lastly, 
billing rates, gross margins, clinic expenses, and setting aside at least three months of operating 
capital to pay bills will need to be calculated and created.  
After getting the PCMH set up, providers will need to work closely with insurance 
companies to make sure that the program can be reimbursed for the appropriate patient care. 
Since the PCMH is created from an existing clinic, where the clinic is owned by a hospital, 
patients will be referred to the clinic by the hospital. However, providers may still need to recruit 
patients, especially if providers see those patients in the hospital as inpatients.  
Organizational Buy-in 
Since starting a PCMH program requires financial funding and stakeholders, a key point 
of the cost-benefit calculation of this innovation is identifying the cost of implementation.  A 
recent study estimated that the average cost for converting a practice into a PCMH is $517,000 
per full-time equivalent (FTE) provider (Zuckerman et al., 2009). Thus it is important to find 
stakeholders who are willing to invest a large sum of money and explain to them how this 
investment will be beneficial in the long run. In this case, the stakeholders in an existing 
hospital-owned clinic will include hospital administrators and the organization that owns the 
hospital. The use of the attention, interest, desire and action (AIDA) business marketing strategy 
will help gain the stakeholders’ attention (SANS Institute, 2001). Attention means providing 
information that will capture the attention of stakeholders and addressing any misconceptions. 
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Interest stands for providing examples of successful PCMH programs at similar facilities to the 
stakeholders in order to gain their interest. Desire stands for increasing the desire of stakeholders 
to value an innovation that may result in improved patient care and satisfaction, and improved 
efficiency. Lastly, action stands for motivating stakeholders to participate in the required 
activities.  
It is also important to engage stakeholders by allowing them the opportunities for 
feedback and voicing of concerns. Consequently, it is also important to offer incentives for 
providers who produce measurable improved outcomes (such as a decrease in readmission rates) 
by giving bonuses for achieving the target of reduced readmission rates after five years of 
evaluation. Providing incentives for stakeholders will improve the chance of organizational buy-
in, thus obtaining funding to start the PCMH program.  
Cost-Benefit Analysis 
 The PCMH program requires much funding to start from the beginning. However, over 
time  the program will help heart failure patients by reducing 30-day hospital readmission rates, 
reducing medical care costs, improving patient outcomes and providing high quality patient care 
(Christensen et al., 2013; Osei-Anto, Audet, Berman, & Jencks, 2010). Thus, to get stakeholders’ 
buy-in, a hypothetical cost-benefit analysis (CBA) was created to show the positive aspects of a 
PCMH program (see figure 3 and 4). 100 HF patients were used for ease of CBA calculations.  
Figure 3. Positive and negative aspect of a PCMH program 
Costs of readmission due to heart failure 
exacerbation 
Benefits of using PCMH to reduce 
readmission rates due to heart failure 
Direct costs: 
• Provider, physician 
• Nursing 
• Medications 
• Room/hospital charge 
Direct costs averted: 
• Decrease penalty from CMS 







• Loss of time from work 
• Loss of income 
• Loss of reimbursement from CMS to 
hospitals 
Productivity losses averted: 
• Work absenteeism costs averted 
• Deaths prevented, so able to preserve 
earnings from work 
• Averted the cost of reduced work 
effectiveness 
 
Figure 4. Cost-Benefit Analysis (CBA) of a PCMH Program 
Cost to implement a PCMH per provider 
(Zuckerman, 2009) 
$ 517,000 
Average readmission rate for HF in US in 
2012 (CMS, 2014) 
24.1% 
Mean cost per stay for HF readmission in 
U.S. in 2012 (AHRQ, 2012) 
$13,634 
  
Out of 100 patients, 24.1% readmission rate 100 x 24.1% = 24.1 = 24 patient readmitted to 
hospital due to HF 
Total expected readmission cost 24 x $13,634 = $327,216 
Reduce readmission rate by 20%, only 80% 
out of 24 readmitted to hospital 
24 x 80% = 19.2 = 19 
Readmission cost after preventing 20% from 
being readmitted 
19 x $13,634 = $259,046 
Cost saved per year by reducing readmission 
by 20% 
$327,216 - $259,046 = $68,170 
  
Money saved by decreasing readmission in 5 
years 
$68,170 x 5 = $340,850 
Total money spent in first year to start a 
PCMH and reducing 20% HF readmission 
$68,170 - $517,000 = $-448,830 
Years needed before reaching break-even 
point of $517,000 
$517,000/$68,170 = 7.6 = 8 years 
 
The benefit of using PCMH to manage care for HF patients post initial discharge from 
the hospital in the first year after implementation, may help save an estimated $68,170 per year 
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per 100 HF patients seen in the PCMH, with a 20% reduction in readmission rate. In the first 
year, the PCMH will not save money. Instead, money will have to be spent up front to fund the 
start of the PCMH, which amounts to $448,830. In addition, if the PCMH operated for five 
years, the money saved by decreasing readmission rates would be $340,850. According to the 
CBA calculation, if healthcare cost remains the same, which is improbable, it will take 
approximately 8 years for the PCMH to hit the break-even point and to potentially recoup more 
than $517,000 in healthcare cost by preventing hospital readmissions.  
The CBA calculations showed that it is difficult to implement a PCMH, even from an 
existing hospital-affiliated clinic because it takes a lot of up-front capital and it can take years to 
begin to see any profit or benefit of money saved in this case. Though it takes a while before one 
can see possible benefit from implementing a PCMH, this type of coordinated healthcare 
delivery system is beneficial in coordinating care and decreasing healthcare cost, especially for 
chronic diseases such as HF (Christensen et al., 2013).  
Evaluating the Effectiveness of the PCMH 
Just like other medical programs, it is important to evaluate the effectiveness of the 
PCMH program. The effectiveness evaluation will give providers some input as to whether the 
patients are benefiting from the program, and whether medical costs decreased or increased after 
the use of a PCMH program to manage HF. In order to evaluate the effectiveness of the PCMH 
model, there should be a decrease in hospital readmission rate by 20%, reach the breakeven point 
of $517,000 and acquire savings from PCMH implementation in eight years. Savings in this case 
means a decrease in the cost of treating HF patients by way of money saved from preventing 
hospital readmission. A program effectiveness survey for staff members should be done in 1 year 
in order to improve the quality of care in the PCMH.  
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In order to measure a decrease in hospital readmission rate by 20% in eight years, 
hospital readmission data will need to be obtained from patients, acute care providers and 
hospitals. It is also important to measure HF compliance outcomes such as dietary compliance 
and medication management. This will determine if the closer contact between patients and 
providers could create better patient outcomes. Lastly, an estimate in reduction of healthcare 
costs related to reduce readmission rates could be calculated. If the healthcare costs to treat 
chronic diseases such as HF decreased, it means that the PCMH worked to help reduce 
readmission rates and healthcare costs.  
In addition to measuring if the cost of treating HF patients in eight years decreased, 
calculations will be made to find out how much money is saved by preventing hospital 
readmissions. In order to calculate the money saved, it is important to assume that the clinic is 
owned and operated by a hospital. If the clinic is not affiliated to any hospital, it will be hard for 
the clinic to save money by preventing hospital readmissions. This is because the calculated 
money saved is not profit that the clinic will receive but money saved by preventing patients 
from being sick. In addition, money saved by preventing readmission takes a while to 
accumulate. Thus the time frame selected was eight years. This time frame will allow the cost 
saved to be significant in terms of preventing hospital readmission.   
Lastly, it is important to develop a survey for staff to participate so the program’s 
effectiveness could be measured through the eyes of the staffs. With the result of the survey, the 
program coordinator could develop a quality improvement plan to improve the program’s 





 One of the limitations of the CBA is that the calculation is based on an estimate of 100 
HF patients per full-time equivalent primary care provider (PCP). It is difficult to obtain a rough 
estimate of the average number of HF patients seen per PCP because every clinic does not see 
the same number and type of patients. Most PCPs do not handle a big number of HF patients in a 
year. Thus the calculation is based on the best estimate available. 
 In addition, for a small clinic that is not affiliated to a hospital, it will take them longer to 
save money on the return on investment because the money is not profit that the clinic will 
receive. It is money that the clinic will save and will not spend by preventing the patient from 
being sick. Thus, it will be more worth it if the PCMH clinic is affiliated to a hospital because 
both the hospital and PCMH clinic will benefit by preventing HF patients from being readmitted 
within 30-days of hospital discharge.  
Nonetheless, PCMH has the potential to benefit other chronic conditions such as diabetes 
mellitus and hypertension (CMS, 2014; Rich, Lipson, Libersky, & Parchman, 2012). It can help 
to decrease the cost of those associated care, thus potentially could lead to an earlier savings 
related to the PCMH. But those chronic conditions were not included for the purpose of this 
CBA since the focus here was on HF.  
 Furthermore, creating a PCMH requires a lot of up-front capital for the initial start-up, 
and it will take years before the stakeholders can begin to see some profit or benefit from the 
PCMH. This may contribute as a difficulty for small, private clinics convert their current practice 
into a PCMH. Lastly, if the PCMH has less patients, then it will take more time for return on 
investments to exceed the cost of turning the clinic into a PCMH. With 100 patients, it takes at 
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least eight years before the clinic hit the breakeven point of $517,000 and recoup that money by 
preventing healthcare cost related to hospital readmissions.  
Conclusion 
Though the concept of PCMH is relatively new, this idea can help to improve the medical 
field, especially for those patients with chronic diseases such as HF. PCMH can provide a more 
patient-centric care by proactively addressing patients’ needs (Christensen et al., 2013). Since 
most studies on PCMH measures patient satisfaction and patient outcomes, future studies could 
include healthcare members’ feelings and satisfaction on using this PCMH model, and how the 
PCMH model helps to reduce/increase the workload of the healthcare members. In addition, 
future studies could also include a survey on the healthcare members’ willingness to change their 
current way of patient care into the PCMH model. By including the thoughts of the healthcare 
members, it will help to decrease team members’ alienation, decrease the feeling of being 
overwhelmed and decrease team members’ resistance to the use of a new concept like PCMH. In 
the long run, this PCMH concept can help to provide a high quality care, reduce 30-day 
readmission rate for HF, reduce medical care cost, better patient outcome and improve patient 
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Background: ACEI has been shown to help decrease mortality, morbidity, rate of re-
hospitalization, and to improve symptoms of heart failure (HF).  However, the rate of ACEI use 
for HF patients remain low despite the recommendations made by the ACCF/AHA Task Force in 
the current 2013 HF guideline.  It is important to increase the use of ACEI because of its positive 
effect on the outcome of HF.  In addition, improper charting could skew the number of patients 
who are actually taking ACEI, making it less than it actually it.  Thus, providers should be on the 
forefront of encouraging ACEI use, especially for HF patients. 
Purpose: The purpose of this study is to evaluate if heart failure patients, aged 18 and over, in a 
primary care clinic receive ACEI therapy as recommended by the current 2013 HF guideline 
written by the American College Cardiology Foundation/American Heart Association 
(ACCF/AHA) Task Force. 
Methods: This is a retrospective chart review study that will assess for documentation of ACEI 
therapy in heart failure patients. Unique medical records meeting the inclusion criteria will be 
reviewed for: the number of patient encounters within the past year, visit day of the week, age, 
ethnicity, gender, type of health insurance (Medicare, Medi-Cal, private insurance, and 
uninsured), select vital signs (systolic blood pressure, diastolic blood pressure, and heart rate), 
ACEI on current active medication list, generic name of ACEI, dose of ACEI, and frequency of 
ACEI per day. If the patient does not have an ACEI on the current, active medication list, the 
chart will be reviewed over the year prior to the patient encounter for documentation of an ACEI 
on active medication list within the past year, an angiotensin-receptor blocker (ARB) on the 
patient medication list, a hydralazine/isosorbide combination on the patient medication list, 
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allergy to ACEI, cough due to ACEI, hypotension due to ACEI, angioedema due to ACEI, and 
documentation of other reason for not being on ACEI. Additionally, a focus group will be held 
after results are analyzed.  The focus group will have result dissemination and questions for 
discussion with providers.  
Results: 63 charts were reviewed, and the results showed that only 20.6% of patients were 
currently taking ACEI for HF.  The most common cause of not taking ACEI was due to allergies. 
Out of the 50 charts that did not have ACEI on the current medication list, 42% did not have any 
type of documentation on why the patient was not on an ACEI.  The focus group found that 
barriers to utilization of ACEI for HF patients included improper or incomplete documentation by 
the medical assistants (MAs), medication list not up to date because the MAs did not take the time 
to go through the list with patients, and patient’s lack of knowledge on the disease process and 
treatment of HF.  
Conclusion: Based on the results of the study, proper medication reconciliation by the patient and 
MAs could help to improve documentation and improve the number of actual ACEI use. 
Decreasing patient load could help improve quality of patient and increase patient satisfaction. 
This will increase patient involvement in the treatment plan, thus increasing rate of adherence to 
ACEI.  Lastly, continuous guideline education will encourage provider to use evidence-based 





Evaluation of Primary Care Providers’ Utilization of ACEI therapy in Heart Failure Patients 
Introduction 
Heart failure (HF), a clinical manifestation of cardiovascular disease, is a chronic 
condition that causes progressive and debilitating damage to the body. In 2012, an estimated 5.7 
million Americans greater than 20 years old had HF, and by the year 2030, the prevalence of HF 
will increase by 46% and greater than 8 million adults will have HF (Mozaffarian et al., 2015). 
According to the AHA (2015) statistical update, in 2011 one in nine deaths was caused by HF, 
with a total death toll of 58,309 during that year. The prevalence of HF also increases with age, 
and the lifetime risk of developing HF for adults 40 years old and greater is one in five. In 
addition, there were approximately 1.8 million outpatient visits with a primary diagnosis of HF 
in 2010. Furthermore, in 2012, the total cost of HF was approximately $30.7 billion, with a 
projected cost increase of 127% to $69.7 billion by the year 2030. This means that the cost of HF 
will increase by $244 per every adult with HF in the U.S (Mozaffarian et al., 2015). This disease 
is also one of the most frequent causes of re-hospitalization in the U.S. with 870,000 new cases 
diagnosed yearly through 2011, and it is associated with high rates of morbidity, mortality and 
cost (Centers for Disease Control and Prevention, 2012). Due to the high rates of prevalence, 
mortality and cost, it is important to prevent HF, and to treat it according to current evidence-
based guidelines.  
 According to the American College of Cardiology/American Heart Association 
(ACC/AHA) practice guideline on the evaluation and management of heart failure, the standard 
therapy in all patients who had a recent or previous history of heart attack or acute coronary 
syndrome, regardless of the presence of HF, will be the prescription of angiotensin-converting 
enzyme inhibitors (ACEIs) and beta blockers (Yancy et al., 2013). Though ACEIs clearly benefit 
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patients with HF, the rate of ACEI use in the U.S. is still relatively low due to its side effects of 
hypotension, hyperkalemia and cough (Gotsman, Rubovinich, & Azaz-Livshits, 2008). 
Background 
ACEIs have been shown to decrease mortality, morbidity, and re-hospitalization in HF 
patients. Studies of the Left Ventricular Dysfunction (SOLVD) investigators (1991); Keyhan, 
Chen, and Pilote (2007); and Hess, Preblick, Hill, Plauschinat, and Yaskin (2009) found that 
ACEIs helped to reduce the rate of re-hospitalization,  decrease mortality, and improve survival 
from congestive HF if a patient was compliant with  the medication. Keyhan, Chen, and Pilote 
(2007) noted that ACEIs decreased mortality in women by 20 percent and by 29 percent in men. 
In the SOLVD study, enalapril, an ACEI, was used in patients with low ejection fraction to see if 
it would reduce the rate of mortality, myocardial infarction and re-hospitalization (SOLVD, 
1991). This study with 2569 participants, which lasted for 41 months, showed that with use of 
enalapril there were decreases in total mortality, in the number of deaths due to cardiovascular 
disease, and in the rate of hospitalization due to worsening HF. In addition, investigators in the 
Prevention of Hypertension With the Angiotensin-Converting Enzyme Inhibitors Ramipril in 
Patients with High-Normal Blood Pressure (PHARAO) study found that over a period of 3 years, 
treatment with ramipril, an ACEI, significantly reduced progression to hypertension 
manifestation by 34.4% as compared with the control group (Luders et al., 2008). Hence, the use 
of ACEI can also slow down the progression of other comorbidities of heart failure, such as 
hypertension.  
The 2013 ACC/AHA practice guideline on HF also recommends the use of hydralazine 
and isosorbide dinitrate (H/I) combination in patients who cannot tolerate ACEIs or ARBs due to 
drug intolerance, hypotension or renal insufficiency (Yancy et al., 2013). The (H/I) combination 
43 
 
has been shown to improve quality of life and hemodynamic output and reduce recurrent 
hospitalizations due to heart failure (Golwala et al., 2013; Anand, Win, Rector, Cohn, & Taylor, 
2014; Taylor et al., 2007; Mullens et al., 2009; Cohn et al., 1986).   
However, ACEIs are not without adverse effects. Studies have shown that providers were 
hesitant to prescribe ACEIs to patients due to adverse effects such as hyperkalemia, increased 
serum creatinine levels and angioedema. Gotsman, Rubovinich, and Azaz-Livshits (2008); 
Beltrami, Zanichelli, Zingale, Vacchini, and Carugo (2011); and Miller, Oliveria, Berlowitz, 
Fincke, and Stang (2012), found that the most common reasons provider discontinued ACEI 
were increased serum potassium levels and elevated serum creatinine levels. In the follow-up 
visit, hypotension and coughing were the main reasons where patients discontinued ACEI use 
(Gotsman, Rubovinich, and Azaz-Livshits, 2008). Furthermore, patients may still contract 
angioedema, even after discontinuation of an ACEI; and ACEIs needed to be used cautiously in 
certain race groups such as African Americans, because the rate of angioedema in that 
population is four times higher as compared to Caucasians (Miller, Oliveria, Berlowitz, Fincke, 
and Stang, 2012). Moreover, the rate of angioedema was higher by 50% in the female population 
than in the male population, and the overall ACEI associated angioedema is 2.7 per 1000 people 
and years of ACE use. 
 Though research shows that ACEIs should be used to treat HF, literature shows that in the 
outpatient setting, there are suboptimal rates of ACEIs prescriptions for HF patients. This could 
be due to decreased guideline familiarity (Shafazand, Yang, Amore, & O’Neal, 2010; Yancy et 
al., 2008), uncertainty about risks versus benefits in treating elderly patients since they are usually 
underrepresented in randomized controlled trials (Fuat, Hungin, & Murphy, 2003; Yancy et al., 
2008), or patient misperceptions of ACEI use (Calvin et al., 2012). Lee et al. (2005) found that for 
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HF patients in the low-, average-, and high-risk groups, ACEIs were prescribed at a rate of 81%, 
73%, and 60% respectively. Patients in the highest risk group for death due to left ventricular 
ejection fractions (LVEFs) of less than 40% and other co-morbidities had the lowest rates of 
ACEI prescription. In the IMPROVE HF study, investigators found that among the eligible older, 
higher-risk HF patients, only 68% received ACEI or ARB (Yancy et al., 2008). In addition, the 
analysis of the Acute Decompensated Heart Failure National Registry (ADHERE) for adherence 
to HF quality-of-care indicators in U.S. hospitals found that only 72% of patients with 
documented left ventricular systolic dysfunction were prescribed ACEI on discharged from the 
hospitals (Fonarow et al., 2005).  
 In the Heart Failure Adherence and Retention Trial (HART) study, investigators studied 
the non-adherence pattern of physicians to prescribing evidence-based therapy according to the 
2005 ACC/AHA HF guideline, and the non-adherence pattern of patients to taking prescribed 
medications (Calvin, et al., 2012). Physician non-adherence would be failure to prescribe ACEI, 
ARB or beta-blocker in the absence of contraindications, or did prescribed medications in the 
presence of known contraindications. The investigators found that 37% of physicians were non-
adherent to evidence-based therapy for HF, while 63% were adherent; 10.8% of patients who 
should be on an ACEI or ARB were not prescribed it, and 74.1% of patients who had 
contraindications to ACEI or ARB were prescribed it (Calvin et al., 2012). This study found that 
non-adherence to evidence-based guideline therapy for HF could be due to patient reasons such as 
depression, cost, cultural factors, effects on sexual function, poor health literacy and medication 
adverse effects.  
Lastly, decreased adherence to guideline-recommended treatment for HF could also be 
due to lack of, as well as improper documentation or the failure to document for 
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contraindications. Steinman et al. (2011) found that 87% of veterans were prescribed either an 
ACEI or an ARB; but when specific reasons such as contraindications to ACEIs or ARBs were 
documented in the chart the rates of ACE or ARB prescribing according to recommended 
guidelines increased to 95%. Improper documentation masked the actual number of ACEI use, 
making it seemed like less patients were prescribed the proper guideline recommended treatment. 
In addition, Atwater et al. (2012) found that only 44% of HF patients with an EF of less than or 
equal to 45% received guideline recommended treatment. After accounting for medical 
contraindications, the number went up to 72%, with an adherence to ACEI guideline 
recommendations for HF of 95%. Thus, proper documentation is important because it will give 
providers a view of patients’ current therapies and any additional therapies that is needed.  
It is important to find out the reasons why providers are not following the recommended 
HF guideline in the use of ACEIs for HF treatment because it could represent missed 
opportunities in treating patients. Continued education in current clinical practice guidelines may 
be needed in helping providers and patients adhere to current clinical practice guidelines and help 
to reduce some of the uncertainties regarding the use of ACEIs in heart failure treatment (Calvin 
et al., 2012).   
Purpose and Aims 
The purpose of this study was to evaluate if HF patients aged 18 and over, in a primary 
care clinic, receive ACEI therapy as recommended by the 2013 HF guideline written by the 
American College Cardiology Foundation/American Heart Association (ACCF/AHA) Task 
Force. 
 The objectives of the study were to assess for frequency of documentation of an ACEI in 
current and active medication lists of patients with HF; assess for documentation of ACEI type, 
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dosages and dosing frequency in the electronic medical record (EMR); assess if an ACEI has been 
an active medication within a year prior to the patient encounter; and, assess for common 
documented reasons that HF patients are not on an ACEI. 
Methods 
 This was a retrospective chart review study. Charts with International Classification of 
Diseases (ICD), 9th revision codes for HF of 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 
428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43 and 428.9 were included in the 
study. A software program called AdvanceMD was used to identify medical records meeting the 
study criteria. This software allowed the PI to insert the required ICD-9 code and the study time 
frame and pull up all the patient encounters for the specific ICD-9 code(s).  
 A discussion session guide (figure 5.) was created to direct a provider discussion session 
after the retrospective chart review portion of the study. The discussion session disseminated de-
identified study results to the provider and discussed barriers and facilitators to proper 
documentation of ACEI, barriers and facilitators to implementing ACEI therapy in the clinic, and 
possible facilitators to providers’ utilization of ACEI therapy in HF patients.    
Human Subject and Research Approval Procedures 
 Permission to conduct the retrospective chart review was obtained from the University of 
Kentucky’s IRB. A waiver of informed consent was obtained for the retrospective chart review 
since this portion of the study used existing patient records, and no direct contact between the 
investigator and subjects would take place. Approval to obtain provider informed consent as 
normal volunteers was also obtained from the University of Kentucky’s IRB. The owner of the 
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clinic gave permission for the study to be completed there, so a letter of agreement for data 
collection was obtained from the study clinic.  
Sample 
 Only charts with an encounter date between January 1, 2014 and December 31, 2014, 
with documentation in the EMR were analyzed. If a patient visited the clinic multiple times 
during this period, only the most recent visit that fell within the period of January 1, 2014 to 
December 31, 2014, was included in the study. Inclusion criteria were 1) adults, both male and 
female, 2) all ethnicities, 3) age greater than or equal to 18 years, 4) a diagnosis of HF, 5) a 
patient encounter at the clinic between January 1, 2014 and December 31, 2014, 6) patients seen 
by consenting providers, and 7) charts with ICD-9 codes of 428.0, 428.1, 428.20, 428.21, 428.22, 
428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43 and 428.9. Exclusion 
criteria were 1) no diagnosis of HF, 2) age less than18 years, 3) a patient encounter not 
documented in the EMR, 4) a patient encounter that was not between January 1, 2014 and 
December 31, 2014, and 5) patient encounters where the PI had documented. Sixty-three medical 
records met the inclusion criteria.         
The sample for the discussion group included all providers who were practicing in the 
clinic from the period of January 1, 2014 to December 31, 2014. Only those providers that signed 
the provider informed consent as a normal volunteer were included in the discussion session. If 
the provider did work at the clinic during the period of January 1, 2014 to December 31, 2014, but 
no longer worked at the clinic at the time of the study, attempts were made to contact and to 
include the providers in the discussion session. Exclusion criteria were 1) providers that did not 
work in the clinic between January 1, 2014 and December 31, 2014, and 2) providers that did not 




All charts meeting the inclusion criteria were included in the study. Unique medical 
records meeting the inclusion criteria were reviewed using a chart audit tool developed by the PI 
(see figure 6.). The chart audit tool was reviewed by a content expert.  Using the chart audit tool, 
identified charts were reviewed for the number of patient encounters within the past year, visit 
day of the week, age, ethnicity, gender, type of health insurance (Medicare, Medi-Cal, private 
insurance, or uninsured), select vital signs (systolic blood pressure, diastolic blood pressure, and 
heart rate), ACEI on current active medication list, generic name of ACEI, dose of ACEI, and 
frequency of ACEI per day. If the patient did not have an ACEI on the current, active medication 
list, the chart was reviewed over the year prior to the patient encounter for documentation of an 
ACEI on active medication list within the past year, an angiotensin-receptor blocker (ARB) on 
the patient medication list, a hydralazine/isosorbide combination on the patient medication list, 
allergy to ACEI, cough due to ACEI, hypotension due to ACEI, angioedema due to ACEI, and 
documentation of other reasons for not being on ACEI.  
 After the completion of the study a discussion session was held with a consenting 
provider and de-identified results were disseminated to the provider at the clinic. Prior to 
discussion session, discussion objectives were created in order to facilitate the discussion with 
providers (see figure 5.) During the discussion session, the primary investigator (PI) reviewed 
the 2013 HF guideline written by the ACCF/AHA Task Force and the retrospective chart review 
results with the provider and discussed the provider’s thoughts on possible barriers and 
facilitators to utilizing ACEI therapy for HF patients in the clinic, barriers and facilitators to 





This retrospective record review took place in an internal medicine clinic in a suburban 
town in Southern California. 
Data collection 
 For data collection, a master code sheet and a chart audit tool were created. The master 
code sheet contained the patient’s chart number, and each chart number were assigned a study 
number. Only the study number and data collected were recorded in the chart audit tool. The 
master code sheet and chart audit tool were always kept separate. The master code sheet was 
kept in a locked file cabinet, in a locked office where it could only be accessed by the PI. The 
chart audit tool was kept on the PI’s password protected computer.  
 By entering the HF ICD-9 codes of 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 
428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43 and 428.9, along with clinic visit date 
range between January 1, 2014 to December 31, 2014 into the AdvanceMD software, 63 charts 
were found that met the inclusion criteria stated above.  
Data analysis 
 Results from the retrospective chart review were analyzed using the IBM Statistical 
Package for the Social Sciences (SPSS) v. 22 software. Descriptive statistics such as frequency, 
percentage, range, mean and standard deviation were used to analyze age, gender, ethnicity, 
insurance type, number of clinic encounters, systolic blood pressure, diastolic blood pressure, 
heart rate, current ACEI therapy, type of ACEI, dose and frequency of ACEI, current ARB 
therapy, current hydralazine/Isosorbide therapy, ACEI allergy, ACEI-associated cough, 
hypotension, angioedema, other reason documented for not being on ACEI, and if a reason was 
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documented for not being on ACEI. Correlations were analyzed using 2-sample T-test and 
Pearson/Fisher’s Exact Test, with statistically significant results set at p < 0.05. 
Reliability and Validity 
 Consistency of data collection was maintained by having the primary investigator (PI) as 
the only person collecting the data for the retrospective chart review and conducting the provider 
focus group interview. To test for content validity, a clinical expert on the topic of HF reviewed 
the chart audit tool and determined the tool appropriate to collect the data needed to meet the 
study objectives.  
Results 
Sample characteristics 
 63 charts met the inclusion criteria for the retrospective chart review. From the 63 charts, 
40 (63.5%) of the patients were female and 23 (36.5%) were male, with a mean age of 69 (range 
= 38-93, SD = 12.0). Most of the patients fall in the age group between 71 to 80 years old, none 
were between 18 to 30 years old, and two were between 91 to 100 years old (See Table 2). 
Patients’ ethnicities included 65.1% White, 25.4% Hispanic, 6.3% Asian, 1.6% Pacific 
Islander/Native Hawaiian, and 1.6% other. Among the 63 charts, 36 (57.1%) had private 
insurance, while 14 (22.2%) had both Medicare and private insurance. Twelve (19.1%) had only 
Medicare, 1 (1.6%) had both Medicare and Medi-Cal, and none were uninsured (Table 2).  
Clinical characteristics 
Comparison of patient clinical characteristics showed the mean systolic blood pressure 
was 121.1 mmHg (range = 96-150, SD = 10.1), the mean diastolic blood pressure was 74.7 
mmHg (range = 58-92, SD = 7.7), and the mean heart rate was 73.4 (range = 50-100, SD = 9.4) 
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(See Table 3). The systolic blood pressure, diastolic blood pressure and heart rate included 
patients who had ACEI in the current, active medication list and who did not have ACEI in the 
current, active medication list. With heart failure as one of the working diagnoses, most patients 
visited the clinic more than once per year, with a mode number of encounter of 8 (mode = 8; 
range = 2-28) in the past year. Lastly, of the 63 charts reviewed, 50 (79.4%) did not have an 
ACEI listed as one of the current medication therapies, as compared to 13 (20.6%) that did 
(Table 3). Furthermore, 24 (38.1%) charts out of the 63 charts reviewed did not have any ACEI, 
ARB, Hydralazine/Isosorbide therapy, or any reasons documented for not being on ACEI (Table 
4). 
Among the 13 charts that listed ACEI as a current therapy, seven (53.8%) were taking 
lisinopril, five (38.5%) were taking ramipril, and one (7.7%) was taking benazepril. In addition, 
the median cumulative dose of ACEI was 5 mg (range = 2.5-40.0; Table 5).  
For those patients who were not taking ACEI at the time of the study (n = 50), 21 (42%) 
of them were on ARB therapy, and three (6%) of them were on hydralazine/isosorbide therapy 
(Table 6). Six (12%) had an allergy to ACEI, two (4%) had ACEI associated cough, and none of 
the 50 charts listed hypotension or angioedema as a reason for not taking ACEI. Four (8%) other 
charts documented other reasons, not including allergy, ACEI associated cough, hypotension or 
angioedema, for not having ACEI on the current active medication list. Out of 50 charts, 26 
(52%) documented a reason for not being on an ACEI while 24 (48%) did not have 
documentation for not being on an ACEI for HF treatment (Table 6).  
In comparing those patients who were taking/not taking ACEI, there was no significant 
difference in the age of those patients who were taking (M = 69.0, SD = 9.6) or not taking (M = 
69.3, SD = 12.9; p = 0.93, two-tailed) ACEI at the time of the study. More females than males 
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were taking ACEI for HF (n = 13; 8 [61.5%] vs. 5 [38.5%]). At the same time, more females 
than males were also not currently taking ACEI for HF treatment (n = 50; 32 [64%] vs. 18 
[36%]). However, the proportion of males who were currently taking ACEI was not significantly 
different from the proportion of females who were currently taking ACEI (Figure 7). There 
appeared to be no association between whether the patients were taking ACEI at the time of 
study and gender, χ2 (1, n = 63) = 0.00, p = >.99, phi = 0.02 (Table 7).  
In the ethnicity category (n = 13), eight (61.5%) White and five (38.5%) Hispanic 
patients had ACEI on the current, active medication list; and (n = 50) 33 (66%) White, 11 (22%) 
Hispanic and six (12%) other ethnicity did not have ACEI on the current, active medication list 
(Figure 8). The proportion of whites who were currently taking ACEI were not significantly 
different from the proportion of Hispanics who were currently taking ACEI. There appeared to 
be no significant association between ethnicity and whether the patients were taking ACEI for 
HF at the time of the chart review, χ2 (2, n = 63) = 2.70, p = 0.26, phi = 0.21 (Table 7). 
When comparing the type of insurance a patient had with taking ACEI at the time of the 
chart review, with n = 13, nine (69.2%) had private insurance, three (23.1%) had both Medicare 
and private insurance, one (7.7%) had only Medicare, and none had combined Medicare/Medi-
Cal or no insurance at all. For those that were not taking ACEI at the time of the study, with n = 
59, 27 (54%) had private insurance, 11 (22%) had both Medicare and private insurance, 11 
(22%) had only Medicare, one (2%) had both Medicare and Medi-Cal, and none was uninsured 
(Figure 9). The proportion of patients that had different insurance, such as Medicare, private, 
Medicare/Medi-Cal and Medicare/private, and were currently taking ACEI were not significantly 
different from the proportion that did not took ACEI at the time of the chart review. There 
appeared to be no significant association between the type of insurance and whether the patients 
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were taking ACEI for HF at the time of the study, χ2 (3, n = 63) = 1.79, p = 0.62, phi = 0.17 
(Table 7). 
 In addition, there was no significant difference in the systolic blood pressure of those 
patients who were currently taking (M = 120.2, SD = 10.1) or not taking (M = 121.5, SD = 10.2; 
p = 0.683, two-tailed) ACEI. Moreover, there also was no significant difference in the diastolic 
blood pressure of those patients who were currently taking (M = 73.7, SD = 6.4) or not taking (M 
= 74.9, SD = 8.1; p = 0.609, two-tailed) ACEI. Lastly, there was no significant difference in the 
heart rate of those patients who were currently taking (M = 72.0, SD = 7.0) or not taking (M = 
73.8, SD = 9.9; p = 0.536, two-tailed) ACEI (Table 7).  
Provider Discussion Session 
 Only one provider, an internal medicine physician, participated in the provider discussion 
session. The discussion session objectives and questions (see figure 5) were used to facilitate the 
provider discussion session. De-identified results were disseminated and the 2013 HF guideline 
written by the ACCF/AHA Task Force was discussed with the provider. In addition, three 
questions were discussed (per the discussion guide). First, the provider was asked what were 
possible barriers and facilitators to implementing ACEI therapy in HF patients at the clinic. The 
provider stated one barrier was patient preference, for example, patients were unwilling to 
continue with ACEI therapy due to side effects such as cough and light-headedness not due to 
hypotension. Another identified barrier was medication lists that were not up-to-date because a 
medication list reconciliation was not performed at the beginning of the patient encounter. 
Lastly, provider preference was identified as playing a role in implementing ACEI therapy in HF 
patients at the clinic. This provider preferred to use Toprol Succinate ER or XL, particularly for 
diastolic HF patients, instead of ACEI. The provider also suggested that medication cost played a 
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part in as both a facilitator and barrier to ACEI implementation in the clinic’s HF patient 
population. The provider stated that patients who had health maintenance organization (HMO) 
insurance were often concerned with medications cost, including the costs of ACEIs. Since 
ACEIs were available for a low cost at some pharmacies, this low cost medication appealed to 
patients and the low cost facilitated its use in the HF population at the clinic.  
 For the second question, the provider was asked to discuss barriers and facilitators to 
proper documentation of ACEI use in the clinic. According to the provider, often, medical 
assistants (MAs) did not obtain or reconcile the patient’s current medication list. The provider 
reported often writing an encounter’s note on paper and then the note was entered into the EMR 
by the MAs at a later time. This contributed to inaccurate, missed, or incomplete documentation. 
The provider reported seeing 50 to 60 patients per day and this patient volume was a barrier to 
proper medication reconciliation and documentation in the current medication list. As for 
facilitators to proper ACEI documentation, the clinic had a medication reconciliation sheet that 
patients could complete while waiting to be seen.  This medication reconciliation sheet that was 
in place during the study period, provided the provider and the MAs a tool to facilitate updating 
the patient’s current medication list. The provider reported improvement in medication 
reconciliation using the medication reconciliation sheet when properly utilized. In addition, the 
new EMR software the clinic began using in December of 2013, made it easier for the provider 
and clinic staff to edit or enter medications in the medication list.  
 The last question asked the provider what could be implemented in order to facilitate 
providers’ use of ACEI therapy in HF patients in this practice. The provider suggested that in 
order to raise awareness of the ACCF/AHA 2013 HF guideline, among the physicians, nurse 
practitioners and physician assistants in the clinic, a meeting to discuss the HF guideline should 
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be held at least biannually. The meeting could be used to discuss any questions about the HF 
guideline and HF treatment options.  
 The provider concluded that the discussion session helped the provider to understand 
some of the documentation problems that the clinic experienced. The provider discussion session 
could help the clinic to improve its documentation process and increase the quality of HF patient 
care in the future.  
Discussion 
The use of ACEI has been shown to decrease mortality rates, cost and re-hospitalization 
of patients due to worsening of HF (The SOLVD investigators, 1991; Hess, Preblick, Hill, 
Plauschinat, & Yaskin, 2009; and Chen et al., 2011). ACEI have also been shown to improve 
functional capabilities and to decrease symptoms of HF patients (Luders et al., 2008). Therefore, 
it is essential that primary care providers treat HF with the appropriate medication, dose and 
frequency of ACEI, according to the 2013 ACCF/AHA HF guideline. However, the rate of ACEI 
use is still relatively low due to its side effects of hypotension, hyperkalemia and cough 
(Gotsman, Rubovinich, & Azaz-Livshits, 2008). The results of the study in this clinic were no 
different. From the retrospective chart review, only 20.6% of the patients had ACEI in the 
current medication list for HF treatment. This low number is disconcerting because the study 
showed that less than 1 out of 4 patients took ACEI for treatment of HF. Since ACEI has been 
shown to help decrease mortality, re-hospitalization and costs of HF, its usage should be higher.  
Though the rate of ACEI use was low, 42% of the patients that were not on an ACEI had 
ARB on the current, active medication list, and 6% had hydralazine/isosorbide therapy. This 
showed that even if patients were not able to use ACEI due to some reasons, ARB or 
hydralazine/isosorbide therapy was used, which followed the recommendations of the 
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ACCF/AHA HF guideline (Yancy et al., 2013). In addition, according to the chart review, 12% 
of the patients were allergic to ACEI, and 4% had ACEI-associated cough. None of the charts 
listed hypotension or angioedema as reasons not to take ACEI. The study results were similar to 
the literature review, in that the main reason for discontinuing ACEI was cough. Though the 
patients did not complain of angioedema or hypotension, the provider would still need to monitor 
the patients’ blood pressure and checked for symptoms of angioedema each time the patients 
come in for a visit.  
Twenty-four (38.1%) of 63 charts reviewed did not indicate the presence of ACEI, ARB, 
or hydralazine/isosorbide combination on the current medication list, did not indicate reasons 
why no ACEI was prescribed such as allergies, cough, hypotension or angioedema, and did not 
indicate other reasons for not being on an ACEI. These patients represented missed opportunities 
for use of ACEI as based on the HF guideline. Since the provider did indicated that 
documentation of medication reconciliation was an issue, it might be possible that similar to 
Atwater et al. (2012), with proper documentation, the number of ACEI utilization might 
increase. If the number of ACEI utilization did not increase, proper documentation of why 
patients were not on an ACEI would allow providers to manage HF appropriately according to 
the next therapy specified in the guideline.  
The chart review also showed that 48% of the HF patients who were not on ACI therapy 
had no documented reasons for why the patients were not on ACEI. This is lower than what 
other literature has found, and could be either due to providers not following guideline 
(Shafazand, Yang, Amore, & O’Neal, 2010; Yancy et al., 2008; Calvin et al., 2012) or due to 
documentation issues (Steinman et al., 2011; Atwater et al., 2012).  
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Furthermore, in the discussion session, the provider ascertained that the biggest barrier 
the clinic has to following the HF guideline is incomplete documentation. Since the provider sees 
many patients each day, the MAs are not able to complete the documentation during the office 
visits. As a result, the provider writes the encounter note including diagnosis, assessment and 
treatment plan on a paper, and the MA then transcribes the provider’s note a later time according 
to what was written on the paper. This transfer of data has the potential for errors.  
The study found no association between age, gender, ethnicity, and insurance type and 
whether the patients were currently taking ACEI for HF. Nevertheless, the study sample did not 
have any patients without insurance. The ACEI treatment of HF patients should not differ based 
on age, gender, ethnicity or insurance. However, the study results differ from the current 
literature, which indicate that age-related differences do play a part in the use of evidence-based 
therapies, such as ACEI, ARBs, and beta-blockers, to manage HF (Forman et al., 2009; Fonarow 
et al., 2009). This difference could be due to the small sample size of the study, or even 
inaccurate charting.  
Lastly, there was no significant difference between the systolic blood pressure, diastolic 
blood pressure and heart rate of the patients who were currently taking ACEI and those who 
were not. The non-significant difference in study result could be due to the small sample size. 
This study result is different than what is found in the current literature, where ACEI has been 
found to improve the functional capabilities of HF patients, and helps to prevent the progression 
of hypertension, thus decreasing the future development of HF (The SOLVD investigators, 1991; 





 One of the limitations of this study was the small number of charts available for the 
review. The small sample makes it difficult to generalize the study to the general HF population.  
 Another limitation of the study was that other medications used to lower blood pressure 
such as diuretics or calcium-channel blockers were not included. These medications could have 
played a part in reducing patients’ blood pressure, thus making it seemed like ACEI did not play 
a part in decreasing patients’ blood pressure (Da Silva, 2010; James et al., 2014; Keyhan, Chen, 
& Pilote, 2007; Luders et al., 2008; The SOLVD investigators, 1991). However, this study was 
specific for ACEI, thus other medications for blood pressure were not included.   
 In addition, upon performing the retrospective chart review, no documentation was found 
to indicate who started the ACEI, ARB or hydralazine/isosorbide therapy for HF treatment. The 
provider also did not remember which patients had the ACEI started in the clinic. Thus, it was 
not possible to figure out if the clinic provider or the specialist started the HF treatment. As a 
result, it was impossible to deduce which provider used evidence-based therapy to treat patients.  
 Another major limitation was the number of providers available for the discussion 
session. Only 1 provider participated. Thus, the results were only the perspective of one clinic 
provider. The answers could contain biased viewpoints from the one provider. Results could 
have been different if there were other providers such as nurse practitioners or physician 
assistants.  
 Lastly, another limitation was that the private insurance was not divided into PPO or 
HMO groups. According to the provider, all the HMO patients were referred to a specialist for 
HF management, while the PPO patients were not referred out. The difference in treatment 
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modalities between the HMO and PPO patients could produce a difference in the presence of 
ACEI in the current, active medication list.  
Implications for Practice 
 It is important that primary care providers treat HF according to the evidence-based 
guidelines for treatment. Providers’ lack of understanding of practice guidelines, improper or 
incomplete charting and patient refusal to use ACEI could be reasons why current ACEI use for 
HF patients in the clinic is only 20.6%.  
 Providers’ lack of practice guideline comprehension could be due to decreased guideline 
familiarity (Fonarow et al., 2008; Shafazand, Yang, Amore, & O’Neal, 2010; Yancy et al., 
2008). Providers need to not only understand guidelines, but also implement guidelines based on 
evidence from research rather than using personal preferences to guide practice (Shafazand, 
Yang, Amore, & O’Neal, 2010). In order to encourage increased evidence-based practice 
guideline use, continuing education is a type of educational strategy that can benefit many 
primary care providers (PCP). Continuing education can help to provide PCPs with current 
evidence-based guideline recommended treatment for HF, translate knowledge from current 
research that benefits HF patients, and increases providers’ awareness and perceptions to HF 
guideline (Parnicka, Wizner, Fedyk-Lukasik, Windak & Grodzicki, 2013). By being 
knowledgeable about HF practice guideline, providers can improve the quality of care for HF 
patients.  
 In addition, having a copy of the guideline uploaded into the computer so it could be 
pulled out at any time electronically for ease of access helps to increase providers’ utilization of 
the guideline (Rattay, Ramakrishnan, Atkinson, Gilson, & Drayton, 2009). Since this clinic does 
not have a clinical decision support software as part of their EMR, adding a software that can 
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show decision support for every patients with HF in the EMR can also help providers to decide 
which treatment, according to the evidence-based practice guideline, should be chosen for the 
patient. By having an EMR with clinical decision support tools for HF, it allows providers to 
manage HF while maintaining patient safety and patient satisfaction at the same time (Vries et 
al., 2013; Schnipper et al., 2008). However, overdependence on the clinical decision support tool 
may not be conducive because the clinical decision support tool could make an inaccurate 
recommendation since technology is not always accurate (Vries et al., 2013; Harrington, 
Kennerly, & Johnson, 2011). Additionally, technology could never replace a person’s thought 
process. Thus having an EMR with a clinical decision support tool is good but overreliance is not 
encouraged.  
 Another method that can help to improve documentation is periodic chart audit for 
compliance. Chart audits can give insight on overall clinic compliance as well as individual 
provider’s compliance, while helping to improve patient safety and helping to reduce potential 
avoidable harm (AHRQ, 2012). Depending on resources available at any primary care clinic, 
chart audits can be performed retrospectively, either electronically or manually, using minimal 
staff provided they are trained in the audit process.  Chart audit results can help to identify areas 
of low compliance, such as medication reconciliation and incomplete documentation, and allow 
providers to tailor improvement strategies according to the audit results (AHRQ, 2012).  
 Furthermore, hiring more PCPs can help to lighten the patient load per provider in any 
clinic. In recent years, chronic diseases had become widespread and poorly controlled, and time 
constraints due to heavy patient load had been attributed as one of the reasons for this concern 
(Ostbye et al., 2005; Yarnall et al., 2003). Additionally, heavy patient load could also contribute 
to clinician burnout, increase medical errors and decrease the quality of patient care (Willard-
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Grace, et al., 2014). Thus, increasing the number of clinicians working in the clinic is one of the 
ways that can help to decrease patient load. With a lighter patient load and the presence of other 
providers, hopefully, these will increase teamwork, increase the exchange of information 
between providers and increase the frequent use of clinical guidelines for evidence-based 
therapies and treatments (Altschuler, Margolius, Bodenheimer, & Grumbach, 2012; Ostbye et 
al., 2005; Willard-Grace, et al., 2014).  
 Moreover, if a provider’s patient load decreases, providers will have time to document 
during each patient’s visit in the EMR. Incomplete documentation can occur if the 
documentation is not completed daily. The presence of many incomplete charts could be a 
precursor to future documentation errors (Steinman et al., 2011; and Atwater et al., 2012). If 
providers document on the EMR and complete it during every patient’s visit, it will help to 
decrease documentation errors or incomplete charting (Steinman et al., 2011; Atwater et al., 
2012). In addition, extra training in EMR documentation can help to decrease the rates of 
documentation errors and improve visit documentation by provider (Haugen, 2012; Keehbauch 
et al., 2012). These will help to improve clinic performance by increasing the quality of patient 
care and increasing patient satisfaction.   
 Lastly, increasing patient education about the side effects of ACEI could help to decrease 
the rate of patient refusal. In this study, 12% of the patient had an allergy to ACEI, while 4% had 
an ACEI-induced cough. None of the study participants had hypotension or angioedema due to 
ACEI.  If patients were educated that taking ACEI could cause ACEI-associated cough and that 
it should eventually decrease as time passes by, patients may be more inclined to stay on ACEI 
even with the cough (Gotsman, Rubovinich, & Azaz-Livshits, 2008). Thus, it is important to 
spend time during each patient’s visit to educate patients about the disease diagnosis and 
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treatment plan. Repetitive education will have better retention, patients will understand the 
reasons why they need treatments for HF, and they will be more involved in the treatment plan 
(Gotsman, Rubovinich, & Azaz-Livshits, 2008). Getting patients involved in the treatment team 
will ensure that patients are more apt to adhere to treatment plans.  
Conclusion 
 Providers must be knowledgeable about the HF guideline and prescribe the appropriate 
treatment for HF, including ACEI when indicated. Patients with HF depend on primary care 
providers as gatekeepers and for disease treatment and management. Rates of ACEI use in those 
with HF can be low due to improper documentation or patients’/providers’ preferences. It will 
require effort to increase the rate of ACEI use through continued education and support for both 
providers and HF patients.  Future studies can explore correlation between proper medication 
documentation with provider-patient ratio, rate of HF guideline use in the presence of clinical 
decision support tool in the EMR, and the effect of providing continuing education on the rate of 
guideline utilization.  ACEI must be used appropriately in treating HF because it can help to 
reduce mortality, morbidity and re-hospitalization, and therefore can help to reduce the rising 





Discussion session objectives 
1. Review appropriate utilization of ACEI therapy in heart failure patients as recommended 
by the 2013 HF guideline written by the American College Cardiology 
Foundation/American Heart Association (ACCF/AHA) Task Force. 
2. Review de-identified study results with clinic providers. 
3. Assess for provider’s thoughts on possible barriers and facilitators to utilizing ACEI 
therapy for heart failure patients in the clinic.  
4. Assess for barriers and facilitators to documentation of ACEI use. 




1. What are barriers and facilitators to implementing ACEI therapy in heart failure 
patients in this clinic?  
2. What are barriers and facilitators to proper documentation of ACEI use in the clinic? 
3. What can be implemented to facilitate providers’ utilization of ACEI therapy in heart 
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Figure 7.   
 










Table 2. Demographic and clinical characteristics of the study sample (N = 63) 
 Mean (SD); Range  
Demographic characteristics  
Age 69.0 (12.0); 38-93 
  
Demographic characteristics n (%) 
Age Group 
   18-30 
   31-40 
   41-50 
   51-60 
   61-70 
   71-80 
   81-90 











   Male 





   White 
   Hispanic 
   Asian 
   Pacific Islander/Native Hawaiian 








   Medicare 
   Uninsured 
   Private  
   Medicare and Medi-Cal 










Table 3. Clinical Characteristics of patients in the clinic (N=63) 
Clinical characteristics Mode; Range 
Number of encounters 8; 2-28 
 
Clinical Characteristics Mean (SD); Range 
Systolic blood pressure 121.2 (10.1); 96-150 
Diastolic blood pressure 74.7 (7.7); 58-92 
Heart rate 73.4 (9.4); 50-100 
 
Table 4. Characteristic of ACEI Therapy Utilization (N=63) 
ACEI Therapy  n (%) 
Current ACEI therapy 
   Yes 




Not on ACEI, ARB, Hydralazine/Isosorbide 
therapy, no documented reasons for not 
being on ACEI 
24 (38.1%) 
 
Table 5. Clinical characteristics of patients on ACEI (n = 13) 
 Median; range or n (%) 
Type of ACEI 
   Benazepril 
   Lisinopril 










Table 6. Reasons why patients are not on ACEI (n = 50) 
 Mean (SD); range or n (%) 
Current ARB therapy 
   Yes 




Current Hydralazine/Isosorbide therapy 
   Yes 





   Yes 




ACEI Associated Cough 
   Yes 





   No 





   No 




Other reason documented 
   Yes 




Reason documented for not being on ACEI 
   Yes 
   No 
 





Table 7. Comparison between patients who are currently taking/not taking ACEI  
 ACEI  
p  
Yes (n = 13) 
 
Mean (SD) or n (%) 
 
No (n = 50) 
 
Mean (SD) or n (%) 
Age 69.0 (9.6) 69.3 (12.9) .93 
Gender 
   Male  









   White 
   Hispanic 











   Medicare 
   Private  
   Uninsured 
   Medicare and Medi-Cal 
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Heart failure (HF) is a preventable disease that has a high treatment cost. According to 
the ACCF/AHA practice guidelines on the evaluation and management of HF, the standard 
therapy in all patients who had a recent myocardial infarction (MI) or a history of MI, regardless 
of HF status, will be the use of ACEI or beta-blockers. Angiotensin II Receptor Blockers (ARBs) 
can be used as an ACEI substitute if the patient has an allergic reaction to ACEI (Yancy et al., 
2013).  
Though ACEI has been shown to decrease mortality rates, cost and re-hospitalization of 
HF patients (The SOLVD investigators, 1991; Hess, Preblick, Hill, Plauschinat, & Yaskin, 2009; 
and Chen et al., 2011), the rate of ACEI use is still relatively low due to its side effects of 
hypotension, hyperkalemia and cough (Gotsman, Rubovinich, & Azaz-Livshits, 2008). This 
study showed that less than 1 out of 4 patients took ACEI for treatment of HF. Of the 63 charts 
reviewed, 38.1% did not indicate the presence of ACEI, ARB, or hydralazine/isosorbide 
combination on the current medication list; did not indicate allergy, cough, or hypotension as the 
reason why no ACEI was prescribed; and did not indicate other reasons for not being on an 
ACEI. These patients represented missed opportunities for use of ACEI based on the HF 
guideline.  
In order to improve the quality of patient care and patient satisfaction, it is important that 
primary care providers (PCPs) utilized evidence-based practice guideline for disease treatment. 
Providers’ lack of knowledge of the practice guidelines, incomplete documentation and patient 
preference could be reasons why current ACEI use is low.  
In order to increase providers’ understanding and implementation of practice guidelines, 
continuing education is an educational strategy that can benefit many PCPs. Continuing 
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education can help to provide PCPs with current evidence-based guideline recommended 
treatment for HF and assist them in translating knowledge from current HF research into practice 
(Parnicka, Wizner, Fedyk-Lukasik, Windak & Grodzicki, 2013). 
Having a copy of the guideline available electronically for ease of access may help to 
increase providers’ utilization of the guideline (Rattay, Ramakrishnan, Atkinson, Gilson, & 
Drayton, 2009). Furthermore, using clinical decision support tools as part of the EMR, can help 
providers to decide which treatment, according to evidence-based practice guidelines, should be 
chosen for a patient. Clinical decision support tools allow providers to manage disease treatment 
while maintaining patient safety and patient satisfaction (Vries et al., 2013; Schnipper et al., 
2008).  
In order to reduce incomplete documentation, extra training in EMR documentation can 
help to decrease the rates of documentation errors and improve visit documentation by providers 
(Haugen, 2012; Keehbauch et al., 2012). The presence of many incomplete charts could be a 
precursor to future documentation errors (Steinman et al., 2011; and Atwater et al., 2012). If 
providers document using the EMR and complete documentation during every patient’s visit, it 
will help to decrease documentation errors or incomplete documentation (Steinman et al., 2011; 
Atwater et al., 2012). If heavy patient load contributes to documentation issues, hiring more 
providers may help to decrease the patient load, thus allowing providers more time to chart and 
to provide safe patient care (Willard-Grace, et al., 2014). 
Lastly, increasing patient education about the side effects of ACEI could help to decrease 
the rate of patient refusal. It is important to spend time during each patient’s visit to educate 
patients about disease diagnosis and treatment plan. Repetitive education increases retention; 
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patients will understand the reasons why they need treatments for HF and will be more involved 
in the treatment plan (Gotsman, Rubovinich, and Azaz-Livshits, 2008). 
Failure to follow the current guideline for HF treatment could lead to increased mortality 
and morbidity for those with HF. The reasons why healthcare providers are not following 
evidence-based HF guidelines must be uncovered and explored to ensure opportunities for 
treating HF patients are not missed. Future studies could focus on the frequency with which 
providers utilize practice guideline for disease treatment and possible interventions to increase 
providers’ ACEI use in HF patients. Utilizing ACEI, in those with HF, is essential to decrease 
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